Company Snapshot
- Ticker
- GILD
- Name
- GILD
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 149657200000.000000
- Volume
- 6,767,829
- Avg Volume (3M)
- 7,084,915
GILD
GILD
Last update recent
120.40
-2.81
(-2.28%)
Market Cap
149657200000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 29086000000.000000
- EPS
- 6.52
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 2.66%
- Net Income
- 8110000000.000000
- Net Margin
- 27.88%
- Payout Ratio
- 49.1%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 18.45
- Forward P/E
- None
- P/S
- 5.15
- P/B
- 6.98
- Beta
- None
- Debt / Equity
- 1.16
- Current Ratio
- 1.45
- Return on Equity
- 0.38%
- Return on Assets
- 0.14%
Technicals & Returns
- Distance vs 200 DMA
- 7.15%
- 200 DMA
- 112.37
- Distance vs 50 DMA
- -0.98%
- 50 DMA
- 121.60
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of Read more
- Name
- GILD
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Daniel P. O'Day
- Employees
- 18,000
- IPO Date
- 1992-01-22
- Phone
- 650 574 3000
- Address
- None
- Website
- https://www.gilead.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-09-13 • $0.77
Latest News
Curated headlines from premium sources.
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains
Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize efficiency. In this environment, it can be …
Gilead's experimental HIV treatment meets main goal in late-stage trial
Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial.
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The doub…
Ameriprise Financial Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD
Ameriprise Financial Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 397.6% in the second quarter, according to the company in its most recent F…
AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD
AQR Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 32.5% in the undefined quarter, according to the company…
Investors Buy Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) was the target of some unusual options trading on Friday. Stock investors acquired 165,669 call options …